



To: Carter BloodCare Customers
From: Hospital Relations
Date: October 14, 2020
Re: COVID-19 Convalescent Plasma Usage

Over the last 10 days, Carter BloodCare has seen an increase in COVID-19 convalescent plasma requests.

Currently, we have an optimal supply of group O and Group A convalescent plasma, but there is minimal to zero inventory of group B and AB convalescent plasma.

While we will import convalescent plasma to supplement our inventories, there is a minimal available supply nationwide.

Impact to Client

- Review and update policies to accept group A or other substitute types for group B and AB convalescent plasma.
- Expect a 48-72 hour delay to fill orders for group B and AB convalescent plasma.
- Imported convalescent plasma units could be labeled as high or low titer. Antibody titer testing is required to be implemented by 12/1/2020 and Carter BloodCare is working on finalizing this process.
- Refer recovered COVID-19 patients to [carterbloodcare.org](https://www.carterbloodcare.org) to consider donating convalescent plasma.

Thank you for your dedication and efforts to help meet patient needs in our community.